Prime Medicine Inc PRME
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.23
- Day Range
- $3.62–4.27
- 52-Week Range
- $2.67–6.94
- Bid/Ask
- $3.77 / $3.78
- Shares Outstanding
- 180.62M
- Market Cap
- $683.64M
- Volume/Avg
- 6M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 158.16
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 146
- Website
- https://www.primemedicine.com
Valuation
|
Metric
|
PRME
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 9.37 |
Price/Sales | 158.16 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PRME
|
|---|---|
Quick Ratio | 3.73 |
Current Ratio | 3.80 |
Interest Coverage | — |
Quick Ratio
PRME
Profitability
|
Metric
|
PRME
|
|---|---|
Return on Assets (Normalized) | −52.66% |
Return on Equity (Normalized) | −162.78% |
Return on Invested Capital (Normalized) | −78.60% |
Return on Assets
PRME
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%!W@>w | LOCK|fNH! | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!#&&$$ | LOCK|@R>Q | $70B | |||
| argenx SE ADR
ARGX
| LOCK|>bf%@Df | LOCK|>%F | $57B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%N@^lq | LOCK|jVnx! | $42B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^!JlmF^ | LOCK|vQC | $35B | |||
| Moderna Inc
MRNA
| LOCK|m%Cdjn | LOCK|>?P | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|jWJt?VG | LOCK|>j^B^ | $26B | |||
| Incyte Corp
INCY
| LOCK|lX&YJ^? | LOCK|Ks | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|ZNKxTX | LOCK|FF | $24B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|vhy^#^ | LOCK|V^x | $18B |
United States